Business Wire

CA-VAULTREE

15.3.2023 14:03:33 CET | Business Wire | Press release

Share
Vaultree Launches Software Development Kit, Making Scalable Data-In-Use Encryption Generally Available to All Enterprises

More than 4,100 publicly disclosed data breaches occurred in 2022, with approximately 22 billion records leaked. Most of it was not encrypted. Vaultree, the Data-In-Use Encryption leader, today announced the general availability of a first-of-its-kind software development kit (SDK) to address this massive need.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005361/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vaultree's first-of-its-kind Fully Functional Data-In-Use Encryption toolkit will transform enterprise security. (Graphic: Business Wire)

Made possible by a series of major cryptographic breakthroughs by the Vaultree team, the SDK is a user-friendly, simple-to-integrate, and easy-to-use fully scalable solution that enables organizations to benefit from Fully Functional Data-In-Use Encryption, allowing for the processing of fully encrypted data without server-side decryption and complex intermediaries or noticeable delays in data processing.

Vaultree developed the solution to address the problems associated with processing completely encrypted data at scale, ensuring that companies no longer need to sacrifice security for performance and are able to keep their data safe at all times with unmatched simplicity and exceptional encrypted data processing rates. Businesses can retain their tech stack, database, code and SQL syntax, follow the rules, and operate without any perceptible changes, with the added benefit of being completely encrypted and at scale. Vaultree's SDK provides protection, including adherence, security and effectiveness. So, in the event of a leak, rather than issuing an apology about the wholesale exposure of sensitive data, companies will be able to inform clients that although their data has been compromised, it is encrypted, meaning it is protected by encryption, an unparalleled level of security.

This layer of protection also makes CISOs' lives easier by solving one of the most difficult challenges in cybersecurity: persistent data encryption, even in the event of a leak, with the world's first Fully Functional Data-In-Use Encryption solution. Encryption technologies to date have not been able to process encrypted data, decrypting it to plain text for processing and therefore impacting organizations' overall data security, making their data readily available to cyber criminals. Vaultree's encryption solution is smarter, quicker, easier, and more efficient than anything else on the market. Truly zero-trust, it allows users to work with fully encrypted data without key disclosure or server-side decryption. Data-In-Use Encryption maintains data encrypted at all times, even during processing. As an added benefit, there are no intermediaries, which translates to zero learning curve or implementation overhead, making adoption seamless.

Ease of integration and use is another critical differentiator of Vaultree's SDK encryption solution. There is no need to be a cryptographer, no intermediaries (such as APIs, proxies or plugins), no change of data architecture, and no code or SQL syntax change. This remarkable adaptability has made the product a prime mover in the market.

"Vaultree's groundbreaking solution is the first of its kind and will change the encryption landscape as we know it. Data security is not only one of today's hot topics but also the topic of tomorrow. Vaultree is leading the way to a safer future," said Rinki Sethi, member of Vaultree's executive board of directors.

Vaultree's SDK encryption solution tackles the drawbacks of both conventional and contemporary encryption methods with a variety of features, including:

  • Close to plaintext processing speed, even at scale
  • Keys reside with the client
  • End-to-end encrypted in use, decrypted only client-side
  • No changes to stack, SQL syntax, data structure, architecture, and network topology
  • Complex processing from fulltext search to computations on randomized encrypted data
  • Performance and scalability at enterprise levels
  • No need for special purpose hardware

Peak performance processing on fully encrypted data enables enterprises to scale to billions of datasets while processing data at speeds similar to unencrypted data processing. Enterprises handling large amounts of sensitive data, including those in financial services, healthcare, pharmaceutical, insurance, retail, telecom, and energy sectors, will be able to mitigate the tremendous economic, cyber, legal, reputational, and business risk of a data breach in plain text — because of the data being encrypted.

"Breaches or leaks will continue happening, no matter how many tools are in the first line of defense, but the second line of defense — encryption — has been neglected for decades because data still has to be decrypted to be worked with. The only way forward is an always-encrypted approach," said Tilo Weigandt, Co-Founder and COO of Vaultree.

Amongst other developments, Vaultree is the first and only (Data-In-Use) encryption solution vendor to partner with Google's AlloyDB for PostgreSQL, leading a new era with a fully functional encryption solution in the cloud. To further expand usage of its revolutionary data protection solution, Vaultree has also partnered with Qrypt. The partnership leverages Qrypt’s ability to independently generate identical symmetric keys at multiple endpoints and quantum-secure future-safe one-time pad encryption paired with Vaultree’s Fully Functional Data-In-Use Encryption to enable fast, future secure data processing in a cloud-first world.

"As it stands, we are the only company globally with the capacity and innovation we have. We are going to grow significantly over the next year enabling organizations with our Data-In-Use encryption technology. We are focusing heavily on bringing this to market fast with our target markets being North America and Europe," said Ryan Lasmaili, Co-Founder and CEO of Vaultree.

About Vaultree

Vaultree has developed the world's first Fully Functional Data-in-Use Encryption solution that solves the industry's fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree's data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005361/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye